Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
1.
J Cutan Pathol ; 2024 Jul 15.
Article in English | MEDLINE | ID: mdl-39005210

ABSTRACT

BACKGROUND: Despite the advancements in the categorization of clinically amyopathic dermatomyositis (CADM), the classification and diagnosis of its subtypes are still challenging. The aim of our study was to describe the clinicopathological features of CADM and assess the differences between amyopathic dermatomyositis (ADM) and hypomyopathic dermatomyositis (HDM). METHODS: This retrospective study included 43 patients with CADM diagnosed at our institution from 2016 to 2020. Patients were subclassed into ADM (n = 30) and HDM (n = 13) groups to assess their clinicopathological differences. RESULTS: All included patients had characteristic cutaneous manifestations of dermatomyositis; 67.4% had myositis-associated auto-antibodies, including ANA (32.6%), RNP (14.0%), anti-Ro52 (9.3%), anti-p155/140 (7.0%), rheumatoid factor (7.0%), anti-NXP-2 (4.7%), anti-MDA5 (2.3%), and anti-Jo-1 (2.3%) antibodies. One patient had associated interstitial lung disease, and another patient had oral squamous cell carcinoma. The histopathological findings included mucin deposition (69.8%), telangiectasia (65.1%), lymphocytic infiltrate (48.8%), vacuolar interface dermatitis (46.5%), and epidermal atrophy (14.0%). Compared to patients with HDM, ADM patients were significantly less likely to have epidermal atrophy, 3.3% versus 38.5% (p = 0.006), and more likely to have mucin deposition, 80.0% versus 46.2% (p = 0.028). CONCLUSION: We described the clinicopathological features of CADM and highlighted the distinctions between ADM and HDM dermatopathologic findings. This information may prove helpful in diagnosing ambiguous lesions.

2.
J Drugs Dermatol ; 20(2): 199-202, 2021 02 01.
Article in English | MEDLINE | ID: mdl-33538555

ABSTRACT

BACKGROUND: Epidermal inclusion cysts (EIC) are one of the most common forms of cysts found on and/or underneath the skin. Inflamed EICs typically show signs and symptoms such as pain and erythema, mimicking cutaneous abscess. However, prior studies have demonstrated at least 20% of lesions are culture negative. OBJECTIVE: To determine the rate of culture positivity in mild inflamed epidermal inclusion cysts, in particular to identify whether empiric antibiotics are warranted. METHODS: In a retrospective chart review 76 cases of inflamed EIC that were mild (lacking systemic symptoms) were analyzed who presented to the department of dermatology at Mount Sinai between 2016–2019. RESULTS: Of cultures taken from inflamed cysts, 47% resulted in no bacterial growth or growth of normal flora, 38.4% resulted in growth of aerobic bacteria with methicillin-resistant Staphylococcus aureus (8%), Staphylococcus lugdunensis (5%), and methicillin-sensitive Staphylococcus aureus (13%) predominating, and 9.3% resulting in growth of anaerobic bacteria with Finegoldia magna, Peptostreptococcus, and Cutibacterium acnes presenting. Review of prescribed treatment regimens often involved antibiotic medication, despite a high prevalence of negative culture. CONCLUSIONS: Almost half of cases of mild inflamed EIC (lacking systemic symptoms) cultured will not grow pathogenic bacteria, therefore incision and drainage with culture and appropriate therapy is a viable therapeutic option in uncomplicated inflamed EIC lesions. In this way, over prescription of antibiotics can be minimized. J Drugs Dermatol. 2021;20(2):199-202. doi:10.36849/JDD.5014.


Subject(s)
Abscess/diagnosis , Anti-Bacterial Agents/therapeutic use , Drainage , Epidermal Cyst/diagnosis , Gram-Positive Bacterial Infections/diagnosis , Abscess/microbiology , Abscess/therapy , Anti-Bacterial Agents/pharmacology , Clinical Decision-Making , Diagnosis, Differential , Drug Resistance, Bacterial , Epidermal Cyst/immunology , Epidermal Cyst/microbiology , Epidermal Cyst/therapy , Epidermis/microbiology , Epidermis/pathology , Epidermis/surgery , Firmicutes/isolation & purification , Gram-Positive Bacterial Infections/immunology , Gram-Positive Bacterial Infections/microbiology , Gram-Positive Bacterial Infections/therapy , Humans , Peptostreptococcus/isolation & purification , Propionibacterium acnes/isolation & purification , Retrospective Studies , Staphylococcus/isolation & purification
3.
Pediatr Dermatol ; 37(6): 1055-1056, 2020 Nov.
Article in English | MEDLINE | ID: mdl-32951249

ABSTRACT

BACKGROUND: Facial cysts can become large (1-5 cm) or giant (>5 cm) on the face. OBJECTIVE: To describe the medical course of large and giant facial cysts in adolescents. METHODS: A case series of 11 patients with large or giant facial cysts seen in an outpatient pediatric dermatology practice. RESULTS: Seven patients underwent incision and drainage with culture of cyst contents growing Cutibacterium acnes in six, while the seventh grew Cutibacterium acnes from a frequently worn hat. All patients were treated with traditional therapeutics for cystic acne including intralesional triamcinolone (n = 9), oral antibiotics (n = 10), and isotretinoin (n = 1). Three patients who did not undergo cyst drainage had persistent symptomatology requiring cyst excision, whereas the seven patients whose cysts were drained (3 on initial management and 4 after recurrence) eventually had complete healing without need for surgery. CONCLUSION: Incision and drainage (I & D) and culture of cyst contents can identify cases of cysts related to Cutibacterium acnes. For some cases of large facial cysts related to Cutibacterium acne, I&D combined with conservative acne management (using standard acne guidelines) can prevent the need for surgical excision in some patients. Prospective studies are needed to determine whether this combination of therapy leads to best outcomes clinically and cosmetically.


Subject(s)
Acne Vulgaris , Cysts , Acne Vulgaris/drug therapy , Adolescent , Anti-Bacterial Agents/therapeutic use , Child , Humans , Neoplasm Recurrence, Local , Prospective Studies
4.
Australas J Dermatol ; 61(3): 237-242, 2020 Aug.
Article in English | MEDLINE | ID: mdl-32109318

ABSTRACT

BACKGROUND/OBJECTIVES: Melasma is a common pigmentary disorder for which oral tranexamic acid has shown some efficacy in previous studies. The aim of this study was to assess the effectiveness of oral tranexamic acid in combination with hydroquinone cream in the treatment of melasma. METHODS: Subjects with moderate-to-severe melasma were enrolled. Group A received hydroquinone 4% cream, sunscreen and oral tranexamic acid, while Group B received hydroquinone 4% cream, sunscreen and placebo capsules for 3 months. All subjects had an additional 3-month follow-up visit on sunscreen alone. The primary outcome measure was change in modified Melasma Area and Severity Index (mMASI) score. In addition, the melanin index was measured using a mexameter. RESULTS: Fifty subjects were enrolled, and all completed the study. There was a 55% reduction in mMASI after 3 months from mean 8.96 (SD 2.45) to 4.0 (SD 1.6) in Group A compared to 10.9% from mean 8.53 (SD 2.04) to 7.6 (SD 2.0) in Group B. Three months after oral and topical therapy was discontinued, there was a 42% decrease in mMASI compared to baseline in Group A (mean 5.1 SD 1.7) vs. 4.7% in Group B (mean 8.1 SD 2.0). No serious adverse events were observed. CONCLUSIONS: A combination of oral tranexamic acid and topical hydroquinone is more effective than hydroquinone alone in the treatment of melasma.


Subject(s)
Antifibrinolytic Agents/therapeutic use , Hydroquinones/therapeutic use , Melanosis/drug therapy , Skin Lightening Preparations/therapeutic use , Tranexamic Acid/therapeutic use , Administration, Cutaneous , Administration, Oral , Adult , Antifibrinolytic Agents/administration & dosage , Double-Blind Method , Drug Therapy, Combination , Female , Humans , Hydroquinones/administration & dosage , Middle Aged , Severity of Illness Index , Skin Lightening Preparations/administration & dosage , Sunscreening Agents/therapeutic use , Tranexamic Acid/administration & dosage , Treatment Outcome
5.
Photodermatol Photoimmunol Photomed ; 34(6): 362-365, 2018 Nov.
Article in English | MEDLINE | ID: mdl-29882991

ABSTRACT

The increased use of ultraviolet (UV) nail lamps in recent years has generated safety concerns of this device. A UV nail lamp is a source of artificial UVA radiation, often used to dry, harden, and cure the nails at home and in the salon. UVA radiation is known to be mutagenic and can cause damage to the DNA, resulting in cutaneous malignancy. Currently, there are only a few studies that have evaluated UV nail lamp irradiation and its potential carcinogenic risk. We review the literature on UV nail lamps, its safety, effect on nails and hands, and the potential role in increasing the risk of cutaneous malignancy. Based on available data, the carcinogenic risk is low; nonetheless, the use of a broad spectrum sunscreen with SPF >30 before UV nail lamp exposure is recommended.


Subject(s)
Nails/pathology , Skin Neoplasms , Ultraviolet Rays/adverse effects , Humans , Skin Neoplasms/epidemiology , Skin Neoplasms/etiology , Skin Neoplasms/metabolism , Skin Neoplasms/pathology
SELECTION OF CITATIONS
SEARCH DETAIL